Insights into Pediatric GATA2-Related MDS: Unveiling Challenges in Clinical Practice

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• GATA2-related myelodysplastic syndrome (GATA2-MDS) is a genetic predisposition with a significant risk of leukemic transformation.
• Key features include monosomy 7, recurrent infections, immunodeficiency, and lymphedema, with prognosis worsening with age.

Purpose of the Study:

• To systematically review the literature on GATA2-MDS, focusing on disease characteristics, diagnosis, management, and outcomes of hematopoietic stem cell transplantation (HSCT).
• To present two pediatric GATA2-MDS cases illustrating clinical and therapeutic challenges.

Main Methods:

• Systematic literature review of eight cohort and case-control studies.
• Inclusion of two pediatric GATA2-MDS cases for real-world clinical insights.

Main Results:

• HSCT is the only curative treatment for GATA2-MDS, but is associated with high rates of graft-versus-host disease (GvHD), unique complications (neurological, thrombotic, infectious), and transplant-related mortality (TRM).
• Post-transplant cyclophosphamide (PT/Cy) strategies may improve survival by reducing GvHD.
• Case studies highlighted rapid disease progression, leukemic transformation, novel mutations, and HSCT complications.

Conclusions:

• Collaborative research is essential to improve understanding and management of GATA2-related myeloid malignancies.
• Further investigation into novel therapeutic strategies and optimizing HSCT protocols, including PT/Cy, is warranted.